- The study met its primary endpoint, demonstrating disease stabilization and safety, along with a dose-response
- Newly released data show evidence of an overall survival benefit for patients treated with therapeutic dose of VB-111
These under-$10 stocks are within range of triggering big breakouts. Here's how to trade them now.
Vascular Biogenics (VBLT) stock is surging in late-morning trading on Monday on positive cancer drug trial results.